Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Melanoma Clinical Trials

A listing of Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (76) clinical trials

In this phase I multiple dose, dose escalation study utilizing a classic 3+3 design. Sequential cohorts of patients will receive AEB1102 IV weekly at one of a series of increasing dose levels. Dose escalation will be dependent on the frequency of specific dose-limiting toxicities in the prior cohort of patients. ...

Phase

Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors

OBJECTIVES: Primary - To determine the tolerance and toxicity profile of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in patients 21 years of age or younger with advanced or refractory solid tumors. - To assess the pharmacokinetics of ipilimumab in patients with ...

Phase

Interferon Alfa-2b in Treating Patients Who Have Undergone Surgery for High-Risk or Metastatic Melanoma

OBJECTIVES: Primary - To determine whether selection of the optimal dose of interferon alfa-2b can be made using signal transduction data in patients who have undergone surgical resection for high-risk or metastatic melanoma. Secondary - To determine the tolerability of this drug when administered at an optimized dose, in terms ...

Phase

Safety Tolerability and Preliminary Efficacy Study of ALS-357 in Patients With Cutaneous Metastatic Melanoma

A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to evaluate the effect of escalating doses of topically applied ALS-357 on histological remission of cutaneous metastatic melanoma and ...

Phase

Natural Killer Cells and Bortezomib to Treat Cancer

Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our ...

Phase

Dasatinib and Bevacizumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot be Removed by Surgery

OBJECTIVES: Primary - To describe the safety and toxicity of the combination of dasatinib and bevacizumab in patients with advanced solid tumors that have progressed on standard therapy. - To find the maximum tolerated dose or recommended phase II dose of this combination. - To describe the biochemical changes in ...

Phase

Clinical Usefulness of Optical Skin Biopsy

Traditional biopsy requires the removal, fixation, and staining of tissues from the human body. Its procedure is invasive and painful. Non-invasive in vivo optical biopsy is thus required, which should provide non-invasive, highly penetrative, three-dimensional (3D) imaging with sub-micron spatial resolution. Optical biopsy based on scanning two-photon fluorescence microscopy (TPFM) ...

Phase

LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab

In this phase I, open-label, multi-arm, multicentre, multi-dose dose escalation study in patients with transdermally accessible tumours; the safety, PK and efficacy of different dosing regimens of LTX-315 will be assessed. Patients will be allocated into 4 separate (parallel) arms depending on the tumour type and the number of lesions ...

Phase

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

Weekly ADI-PEG 20 will be cohort dose escalated (18, 27 and 36 mg/m2), with pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 both given every 3 weeks. Subjects may receive a maximum of 6, 3-week cycles of ADIPemCis for a total of 18 weeks of treatment. Subjects with NSCLC may receive ...

Phase

Treatment of Advanced Melanoma With MK-3475 and Peginterferon

This is a safety and dose-seeking study of combination MK-3475 and peginterferon alfa-2b for adult patients (≥18) with advanced melanoma. A total of 32 patients will be included. Subjects will undergo screening evaluations to determine eligibility within 28 days (4 weeks) of the first dose. Each 21 day dosing period ...

Phase